Ketamine-Assisted Therapy: What the Clinical Evidence Says About Depression, PTSD, and Pain

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making changes to your medications, supplements, or health regimen.

For decades, treatment-resistant depression left millions of patients cycling through failed antidepressants with little hope. Then ketamine — once known primarily as an anesthetic and recreational drug — emerged as one of the most significant breakthroughs in psychiatric medicine in a generation. Today, ketamine-assisted therapy is FDA-cleared, clinically validated, and reshaping how physicians approach depression, PTSD, and chronic pain.

What Is Ketamine-Assisted Therapy?

Ketamine is a dissociative anesthetic that has been used safely in medical settings since the 1970s. At sub-anesthetic doses, it produces rapid antidepressant effects — often within hours — that can last days to weeks. This speed is remarkable compared to traditional antidepressants, which typically require four to six weeks to show benefit.

There are two primary clinical forms:

• IV ketamine infusions — administered in a clinical setting, typically over 40–60 minutes, often in a series of six infusions over two to three weeks
• Esketamine (Spravato) — an FDA-approved nasal spray (the S-enantiomer of ketamine) for treatment-resistant depression and major depressive disorder with suicidal ideation, administered in certified healthcare settings

How Does It Work?

Unlike SSRIs and SNRIs that target serotonin and norepinephrine systems, ketamine works primarily through the glutamate system — specifically as an NMDA receptor antagonist. This triggers a cascade of neuroplastic changes:

• Rapid synaptogenesis — ketamine stimulates the growth of new synaptic connections in the prefrontal cortex, an area often structurally diminished in depression
• BDNF release — brain-derived neurotrophic factor surges after ketamine administration, supporting neuronal repair and resilience
• Default mode network modulation — ketamine temporarily disrupts rigid, ruminative thought patterns associated with depression and PTSD

A landmark 2019 study published in Science demonstrated that ketamine's antidepressant effects are mediated partly through opioid receptors as well, adding nuance to the mechanism picture ([PMID: 30846613](https://pubmed.ncbi.nlm.nih.gov/30846613/)).

Clinical Evidence for Depression

The evidence base for ketamine in treatment-resistant depression (TRD) is substantial:

• A 2021 meta-analysis in JAMA Psychiatry found that IV ketamine produced response rates of approximately 50–70% in TRD patients, with effects emerging within 24 hours ([PMID: 33656563](https://pubmed.ncbi.nlm.nih.gov/33656563/))
• The FDA approved esketamine (Spravato) in 2019 based on Phase III trials showing significant reduction in MADRS depression scores versus placebo
• A 2023 NIH-funded trial found that ketamine outperformed electroconvulsive therapy (ECT) for non-psychotic TRD in speed of response and patient preference ([NIH ClinicalTrials.gov NCT03113968](https://clinicaltrials.gov/ct2/show/NCT03113968))

Who Qualifies?

Ketamine therapy is typically considered for patients who:

• Have failed two or more adequate antidepressant trials
• Have active suicidal ideation requiring rapid intervention
• Cannot tolerate standard antidepressant side effects

Ketamine for PTSD

Post-traumatic stress disorder is another frontier where ketamine shows promise. The glutamate system plays a central role in fear memory consolidation and extinction — processes disrupted in PTSD.

• A 2021 randomized controlled trial in Nature Medicine found that repeated ketamine infusions significantly reduced PTSD symptom severity compared to midazolam (active placebo), with effects lasting up to two weeks post-treatment ([PMID: 33820975](https://pubmed.ncbi.nlm.nih.gov/33820975/))
• Researchers hypothesize that ketamine's window of neuroplasticity may enhance the effectiveness of concurrent trauma-focused psychotherapy
• The VA and DoD are actively funding ketamine research for combat-related PTSD

Ketamine for Chronic Pain

Beyond psychiatry, ketamine has a well-established role in pain medicine:

• Complex regional pain syndrome (CRPS) — low-dose ketamine infusions are used off-label and show meaningful pain reduction in refractory cases
• Fibromyalgia and neuropathic pain — small trials suggest benefit, though evidence is less robust than for depression
• Opioid-sparing effects — ketamine reduces opioid requirements in post-surgical and chronic pain settings, an important consideration given the opioid crisis

The American Society of Regional Anesthesia and Pain Medicine (ASRA) published consensus guidelines in 2018 supporting ketamine use for chronic pain in appropriate clinical contexts.

Safety Profile and Risks

Ketamine is not without risks, and appropriate patient selection and clinical oversight are essential:

Common Side Effects

• Dissociation and perceptual disturbances during infusion
• Nausea and dizziness
• Transient blood pressure elevation
• Headache

Serious Concerns

• Abuse potential — ketamine has recreational misuse potential; clinical protocols include strict monitoring
• Bladder toxicity — chronic high-dose recreational use is associated with ketamine cystitis; therapeutic doses at clinical frequencies carry much lower risk
• Cardiovascular effects — contraindicated in uncontrolled hypertension or unstable cardiac disease
• Psychosis risk — not recommended for patients with active psychotic disorders

The FDA requires esketamine (Spravato) to be administered under a Risk Evaluation and Mitigation Strategy (REMS) program, meaning patients must be monitored for at least two hours post-dose in a certified healthcare setting.

What to Expect During Treatment

A typical IV ketamine infusion series involves:

1. Medical evaluation — psychiatric and medical history, contraindication screening

2. Six infusions over two to three weeks (the standard induction protocol)

3. Integration sessions — many clinics pair infusions with psychotherapy to help patients process insights

4. Maintenance infusions — monthly or as-needed boosters to sustain response

Costs vary widely: IV ketamine infusions typically run $400–$800 per session and are rarely covered by insurance. Esketamine (Spravato) has better insurance coverage given its FDA approval status.

The Future of Ketamine Research

Researchers are actively investigating:

• Oral ketamine formulations for maintenance therapy
• Psychedelic-assisted therapy combinations — pairing ketamine with structured psychotherapy protocols
• Biomarkers to predict who will respond, including glutamate levels and neuroimaging signatures
• Novel NMDA modulators inspired by ketamine's mechanism but with improved safety profiles

---

Take Control of Your Health Data

Ready to cross-reference your medications, supplements, and lab results in one place? [Health Intelligence Analyzer](/) helps you identify potential interactions, flag abnormal lab values, and optimize your health regimen with AI-powered insights. Start your free analysis today.